Abbott Launches XIENCE Sierra Coronary Stent System in India

The launch follows regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) in February.

Abbott, a prominent player in the healthcare technology sector, has unveiled the XIENCE Sierra, an advanced everolimus-eluting coronary stent system, in India. 

This launch comes after receiving regulatory clearance from the Central Drugs Standard Control Organisation (CDSCO) earlier this year, positioning the company to address the country's evolving needs of heart patients.

Commenting on the launch, Tushar Sharma, GM,  Abbott’s vascular business in India and South Asia, said, "XIENCE Sierra is being introduced in India to offer physicians the means to address coronary artery disease, even in complex cases effectively. With cardiovascular diseases emerging as a significant health challenge in India, it is imperative to equip healthcare professionals with innovative tools for optimal patient care."

More on XIENCE Sierra

According to Abbott's official statement, cardiovascular diseases are a leading cause of mortality among non-communicable diseases in India. 

The company highlights the high prevalence of coronary artery disease (CAD) among Indians, particularly those with diabetes, underlining the critical need for advanced medical interventions such as the XIENCE Sierra coronary stent system.

Abbott's XIENCE Sierra integrates cutting-edge technology, featuring a cobalt-chromium alloy metal stent coated with the drug Everolimus and a specialized polymer coating for controlled drug delivery. 

The system's advanced design enhances deliverability, allowing physicians to address difficult-to-treat lesions flexibly and precisely. 

The company asserts the stent's efficacy in clinical trials involving over 120,000 patients, particularly in narrowed lesions and complex conditions.

Abbott’s Latest Advancements

In addition to the XIENCE Sierra launch, Abbott has introduced the GLP System Track, an automated solution to improve diagnostic services in India.

Abbott's latest offering, the GLP System Track, is designed to assist diagnostic centers in managing large volumes of samples, addressing the growing demand for diagnostic services amid India's rising burden of chronic diseases. 

The automated solution aims to enhance operational efficiency and optimize performance in diagnostic laboratories, improving healthcare delivery nationwide.

Additionally, in November, Abbott introduced the FreeStyle LibreLink app in India, offering users of the FreeStyle Libre glucose monitoring system the convenience of checking readings on their mobile phones without needing finger pricking.

The app, compatible with both iPhone and Android smartphones, provides real-time glucose data and enables accessible information sharing with healthcare providers.

With a focus on innovation and efficacy, these developments hold promise for enhancing patient outcomes and strengthening healthcare infrastructure in the country.

Abbott also introduced its vascular imaging platform, which features Ultreon 1.0 Software in India. This intra-vascular imaging software merges optical coherence tomography (OCT) with AI capabilities, providing medical professionals with a comprehensive view of blood flow and blockages within coronary arteries.

Per the company, a distinguishing feature of this imaging software is its ability to automatically distinguish between calcified and noncalcified blockages, assess the severity of calcium-based blockages, and measure vessel diameter.